# v3.14

## Related releases

## Data changes

Alteration:
AR AR-V7, Mutation Effect Description Updated
BCOR Internal Tandem Duplication Added
BRAF Kinase Domain Duplication, Mutation Effect Description Updated
BRCA1 L22S, Mutation Effect Description Updated
KIT X550_splice, Mutation Effect Description Updated
KIT P577del, Mutation Effect Description Updated
KMT2A Partial Tandem Duplication Added
MET Amplification, Mutation Effect Description Updated
MET D1010 Name Changed
	 New: D1010
	 Old: D1010mis
MET Y1003 Name Changed
	 New: Y1003
	 Old: Y1003mut
MET Y1003 Deleted
MET Y1003, Oncogenicity Updated
	 New: Likely
	 Old: 
NF1 L90R, Mutation Effect Description Updated
NF1 L90P Added
NF1 L90P, Mutation Effect Description Updated
RAD51B R47*, Mutation Effect Description Updated
RAD51B S207L Deleted
RAD51B Truncating Mutations, Mutation Effect Description Updated
RAD51D S207L Added
RAD54L G325R, Mutation Effect Description Updated
RET A919V, Mutation Effect Description Updated
RET A919V, Oncogenicity Updated
	 New: Inconclusive
	 Old: Likely
TSC2 S1498N, Mutation Effect Description Updated

Evidence:
ALK Fusions, Inflammatory Myofibroblastic Tumor, Lorlatinib 2 Added
ALK Fusions, Inflammatory Myofibroblastic Tumor, Tumor Type Summary Updated
BRAF V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib  Updated
BRAF V600E, Biliary Tract Cancer, NOS, Tumor Type Summary Updated
BRAF V600E, Biliary Tract Cancer, NOS, Dabrafenib + Trametinib 3A Deleted
BRAF V600E, Biliary Tract Cancer, NOS, Dabrafenib + Trametinib 2 Added
EGFR A763_Y764insFQEA (Exon 20 in-frame insertion), Non-Small Cell Lung Cancer, Erlotinib  Updated
ERBB2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Trastuzumab Deruxtecan  Updated
ERBB2 Amplification, Colorectal Cancer, Trastuzumab Deruxtecan  Updated
KIT D816, D820, N822, Y823D, C809G, A829P (Sensitizing exon 17 and 18 mutations), Gastrointestinal Stromal Tumor, Imatinib  Updated
MET Amplification, Non-Small Cell Lung Cancer, Crizotinib  Updated
NTRK1 Fusions, All Solid Tumors, Repotrectinib 3A Added
NTRK1 Fusions, All Solid Tumors, Repotrectinib  Updated
NTRK2 Fusions, All Solid Tumors, Repotrectinib 3A Added
NTRK2 Fusions, All Solid Tumors, Repotrectinib  Updated
NTRK3 Fusions, All Solid Tumors, Repotrectinib 3A Added
NTRK3 Fusions, All Solid Tumors, Repotrectinib  Updated
ROS1 Fusions, Non-Small Cell Lung Cancer, Repotrectinib 3A Added
ROS1 Fusions, Non-Small Cell Lung Cancer, Repotrectinib  Updated
